PGNYNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
Progyny, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$27.84+0.98 (+3.65%)
Close on Oct 19, 2026
- Market cap
- $2.29B
- P/E (TTM)
- 30.3
- Dividend yield
- –
Share price
+$8.50 (+43.95%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Progyny, Inc. grew revenue 5.5% to $1.31B over the twelve months to Jun 30, 2026. Operating income rose 46.1% to $112.13M, moving the operating margin from 6.2% to 8.6%. Free cash flow was $178.38M, down 6.2% from a year earlier.
Revenue
$1.31B
+5.5% vs. a year earlier
Operating income
$112.13M
+46.1% vs. a year earlier
Free cash flow
$178.38M
-6.2% vs. a year earlier
EPS, diluted
$0.92
+55.9% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.29B
- P/E ratio
- 30.3
- Price to sales
- 1.74
- Price to book
- 5.05
- Dividend yield
- –
- Free cash flow yield
- 7.80%
Fundamentals
- Revenue
- $1.31B
- Net income
- $78.63M
- EPS, diluted
- $0.92
- Free cash flow
- $178.38M
- Book value per share
- $5.52
- Diluted shares
- 82M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
$1.31B+5.5% YoY
Gross profit
$322.09M+16.1% YoY
Operating income
$112.13M+46.1% YoY
Net income
$78.63M+48.0% YoY
EPS, diluted
$0.92+55.9% YoY
Free cash flow
$178.38M-6.2% YoY
Reported periodTrailing twelve months